Tolerance of the induction and consolidation courses
| . | Cycle . | |||
|---|---|---|---|---|
| COPADM . | CYVE . | |||
| 1 . | 2 . | 1 . | 2 . | |
| Patients, no. | 62 | 56 | 52 | 48 |
| Fever, no. (%) | 52 (83) | 43 (76) | 47 (90) | 37 (77) |
| Patients with nadir neutrophil count less than 0.5 ×109/L, no. (%) | 59 (95) | 53 (94) | 50 (96) | 46 (96) |
| Patients with nadir platelet count less than 50 ×109/L, no.(%) | 49 (79) | 38 (68) | 50 (96) | 48 (100) |
| No. of hospitalization days, median (range) | 22 (6-43) | 18 (5-32) | 16 (5-34) | 15 (5-30) |
| MTX dosage more than 75% theoretical, no. (%) | 46 (74) | 50 (89) | — | — |
| Adriamycin dosage more than 75% theoretical, no. (%) | 58 (93.5) | 53 (94) | — | — |
| ARA-C dosage more than 75% theoretical, no. (%) | — | — | 41 (79) | 32 (66) |
| Reason for stopping treatment* | ||||
| Progressive disease† | 0 | 0 | 4 | 2 |
| Toxicity or death‡ | 6 | 4 | 0 | 0 |
| Death | ||||
| BL related | 1 | 1 | 0 | 0 |
| Treatment related | 5 | 2 | 0 | 0 |
| . | Cycle . | |||
|---|---|---|---|---|
| COPADM . | CYVE . | |||
| 1 . | 2 . | 1 . | 2 . | |
| Patients, no. | 62 | 56 | 52 | 48 |
| Fever, no. (%) | 52 (83) | 43 (76) | 47 (90) | 37 (77) |
| Patients with nadir neutrophil count less than 0.5 ×109/L, no. (%) | 59 (95) | 53 (94) | 50 (96) | 46 (96) |
| Patients with nadir platelet count less than 50 ×109/L, no.(%) | 49 (79) | 38 (68) | 50 (96) | 48 (100) |
| No. of hospitalization days, median (range) | 22 (6-43) | 18 (5-32) | 16 (5-34) | 15 (5-30) |
| MTX dosage more than 75% theoretical, no. (%) | 46 (74) | 50 (89) | — | — |
| Adriamycin dosage more than 75% theoretical, no. (%) | 58 (93.5) | 53 (94) | — | — |
| ARA-C dosage more than 75% theoretical, no. (%) | — | — | 41 (79) | 32 (66) |
| Reason for stopping treatment* | ||||
| Progressive disease† | 0 | 0 | 4 | 2 |
| Toxicity or death‡ | 6 | 4 | 0 | 0 |
| Death | ||||
| BL related | 1 | 1 | 0 | 0 |
| Treatment related | 5 | 2 | 0 | 0 |